文献速递类风湿关节炎

SB2 生物类似药与参照英夫利西单抗治疗 54 周的双盲试验比较:临床、结构和安全性结果

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

这项 III 期双盲平行组多中心研究将 584 例甲氨蝶呤疗效不佳的中重度类风湿关节炎患者按 1:1 随机分配接受 SB2 或参照英夫利西单抗 3 mg/kg 治疗。结果显示,至 54 周时两组在影像学进展(改良总 Sharp 评分平均差值:SB2 0.38,INF 0.37)、ACR 应答、DAS28、CDAI、SDAI、安全性和抗药抗体方面均具有可比性。

要点

  • SB2 与参照英夫利西单抗在 54 周内的疗效、安全性和免疫原性相似。
  • 1 年时两组影像学进展相当(改良总 Sharp 评分平均差值:SB2 0.38,INF 0.37)。

核心结论

  • SB2 在中重度类风湿关节炎患者中至 54 周维持与参照英夫利西单抗相似的疗效、安全性和免疫原性,1 年时影像学进展相当。

研究设计与样本

  • III 期双盲、平行组、多中心研究,共随机分配 584 例患者接受 SB2(n=291)或参照英夫利西单抗(n=293)。

主要发现

  • 1 年时影像学进展率在 SB2 与参照英夫利西单抗之间具有可比性(改良总 Sharp 评分平均差值:SB2 0.38,INF 0.37)。
  • 至 54 周时 ACR 应答、28 关节 DAS、CDAI 和 SDAI 在 SB2 与参照英夫利西单抗之间具有可比性。
  • 治疗中出现的不良事件和抗药抗体发生率在治疗组间具有可比性。
  • 从基线至 54 周,疗效、安全性和免疫原性的可比趋势保持一致。
  • 剂量增加模式在 SB2 与参照英夫利西单抗之间也具有可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: SB2 is a biosimilar to the reference infliximab (INF). Similar efficacy, safety and immunogenicity between SB2 and INF up to 30 weeks were previously reported. This report investigates such clinical similarity up to 54 weeks, including structural joint damage. METHODS: In this phase III, double-blind, parallel-group, multicentre study, patients with moderate to severe RA despite MTX were randomized (1:1) to receive 3 mg/kg of either SB2 or INF at 0, 2, 6 and every 8 weeks thereafter. Dose escalation by 1.5 mg/kg up to a maximum dose of 7.5 mg/kg was allowed after week 30. Efficacy, safety and immunogenicity were measured at each visit up to week 54. Radiographic damage evaluated by modified total Sharp score was measured at baseline and week 54. RESULTS: A total of 584 patients were randomized to receive SB2 (n = 291) or INF (n = 293). The rate of radiographic progression was comparable between SB2 and INF (mean modified total Sharp score difference: SB2, 0.38; INF, 0.37) at 1 year. ACR responses, 28-joint DAS, Clinical Disease Activity Index and Simplified Disease Activity Index were comparable between SB2 and INF up to week 54. The incidence of treatment-emergent adverse events and anti-drug antibodies were comparable between treatment groups. Such comparable trends of efficacy, safety and immunogenicity were consistent from baseline up to 54 weeks. The pattern of dose increment was also comparable between SB2 and INF. CONCLUSION: SB2 maintained similar efficacy, safety and immunogenicity with INF up to 54 weeks in patients with moderate to severe RA. Radiographic progression was comparable at 1 year. TRIAL REGISTRATION: ClinicalTrials.gov (http://clinicaltrials.gov; NCT01936181) and EudraCT (https://www.clinicaltrialsregister.eu; 2012-005733-37).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Smolen JS, Choe JY, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology (Oxford). 2017. PMID: 28957563. doi:10.1093/rheumatology/kex254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。